Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1986 Mar 1;134(5):495–501.

Amiodarone for refractory cardiac arrhythmias: 10-year study.

D Leak, J N Eydt
PMCID: PMC1490798  PMID: 3948063

Abstract

Over a 10-year period 130 patients with drug-resistant cardiac arrhythmias associated mainly with coronary artery disease and its complications were treated with amiodarone. The drug controlled all the tachyarrhythmias associated with the Wolff-Parkinson-White syndrome, 95% of the ventricular arrhythmias, including recurrent ventricular tachycardia and fibrillation, and 92% of the supraventricular arrhythmias. The maximum duration of therapy was 111 months and the mean 34 months. Side effects occurred in 34% of the patients, and there was one withdrawal from therapy per 15.3 patient-years of treatment. The commonest cause of withdrawal was nausea, which was significantly related (p less than 0.01) to a drug interaction with digoxin and diuretics. Reversible neurologic complications occurred in eight patients (6%), and acute myositis was recognized for the first time. Pulmonary infiltration developed in four patients (3%), who were receiving 600 mg of amiodarone per day. The rates of side effects and of withdrawal from therapy differed significantly between the patients whose maintenance doses were 600 and 200 mg/d, at 59% v. 6% (p less than 0.01) and 32% v. 0% (p less than 0.05) respectively. Thus, amiodarone is a very effective antiarrhythmic that can be administered over long periods with acceptable rates of side effects and withdrawal provided the minimal effective dose is used; 400 mg/d or less is desirable.

Full text

PDF
495

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón-Segovia D. Drug-induced lupus syndromes. Mayo Clin Proc. 1969 Sep;44(9):664–681. [PubMed] [Google Scholar]
  2. DAVIES P., LEAK D., ORAM S. QUINIDINE-INDUCED SYNCOPE. Br Med J. 1965 Aug 28;2(5460):517–520. doi: 10.1136/bmj.2.5460.517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fogoros R. N., Anderson K. P., Winkle R. A., Swerdlow C. D., Mason J. W. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation. 1983 Jul;68(1):88–94. doi: 10.1161/01.cir.68.1.88. [DOI] [PubMed] [Google Scholar]
  4. Graboys T. B., Podrid P. J., Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J. 1983 Oct;106(4 Pt 2):870–876. doi: 10.1016/0002-8703(83)90009-1. [DOI] [PubMed] [Google Scholar]
  5. Haffajee C. I., Love J. C., Canada A. T., Lesko L. J., Asdourian G., Alpert J. S. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation. 1983 Jun;67(6):1347–1355. doi: 10.1161/01.cir.67.6.1347. [DOI] [PubMed] [Google Scholar]
  6. Hamer A., Peter T., Mandel W. J., Scheinman M. M., Weiss D. The potentiation of warfarin anticoagulation by amiodarone. Circulation. 1982 May;65(5):1025–1029. doi: 10.1161/01.cir.65.5.1025. [DOI] [PubMed] [Google Scholar]
  7. Harris L., McKenna W. J., Rowland E., Holt D. W., Storey G. C., Krikler D. M. Side effects of long-term amiodarone therapy. Circulation. 1983 Jan;67(1):45–51. doi: 10.1161/01.cir.67.1.45. [DOI] [PubMed] [Google Scholar]
  8. Heger J. J., Prystowsky E. N., Jackman W. M., Naccarelli G. V., Warfel K. A., Rinkenberger R. L., Zipes D. P. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981 Sep 3;305(10):539–545. doi: 10.1056/NEJM198109033051002. [DOI] [PubMed] [Google Scholar]
  9. Ingram D. V. Ocular effects in long-term amiodarone therapy. Am Heart J. 1983 Oct;106(4 Pt 2):902–905. doi: 10.1016/0002-8703(83)90014-5. [DOI] [PubMed] [Google Scholar]
  10. Kaski J. C., Girotti L. A., Messuti H., Rutitzky B., Rosenbaum M. B. Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. Circulation. 1981 Aug;64(2):273–279. doi: 10.1161/01.cir.64.2.273. [DOI] [PubMed] [Google Scholar]
  11. Keren A., Tzivoni D., Gavish D., Levi J., Gottlieb S., Benhorin J., Stern S. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981 Dec;64(6):1167–1174. doi: 10.1161/01.cir.64.6.1167. [DOI] [PubMed] [Google Scholar]
  12. Kosowsky B. D., Taylor J., Lown B., Ritchie R. F. Long-term use of procaine amide following acute myocardial infarction. Circulation. 1973 Jun;47(6):1204–1210. doi: 10.1161/01.cir.47.6.1204. [DOI] [PubMed] [Google Scholar]
  13. Leak D., Eydt J. N. Control of refractory cardiac arrhythmias with amiodarone. Arch Intern Med. 1979 Apr;139(4):425–428. [PubMed] [Google Scholar]
  14. Marchlinski F. E., Gansler T. S., Waxman H. L., Josephson M. E. Amiodarone pulmonary toxicity. Ann Intern Med. 1982 Dec;97(6):839–845. doi: 10.7326/0003-4819-97-6-839. [DOI] [PubMed] [Google Scholar]
  15. McGovern B., Garan H., Kelly E., Ruskin J. N. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed) 1983 Jul 16;287(6386):175–180. doi: 10.1136/bmj.287.6386.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Moysey J. O., Jaggarao N. S., Grundy E. N., Chamberlain D. A. Amiodarone increases plasma digoxin concentrations. Br Med J (Clin Res Ed) 1981 Jan 24;282(6260):272–272. doi: 10.1136/bmj.282.6260.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nademanee K., Hendrickson J. A., Cannom D. S., Goldreyer B. N., Singh B. N. Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J. 1981 Jun;101(6):759–768. doi: 10.1016/0002-8703(81)90613-x. [DOI] [PubMed] [Google Scholar]
  18. Nademanee K., Singh B. N., Hendrickson J., Intarachot V., Lopez B., Feld G., Cannom D. S., Weiss J. L. Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med. 1983 May;98(5 Pt 1):577–584. doi: 10.7326/0003-4819-98-5-577. [DOI] [PubMed] [Google Scholar]
  19. Podrid P. J., Lown B. Amiodarone therapy in symptomatic, sustained refractory atrial and ventricular tachyarrhythmias. Am Heart J. 1981 Apr;101(4):374–379. doi: 10.1016/0002-8703(81)90124-1. [DOI] [PubMed] [Google Scholar]
  20. Podrid P. J., Schoeneberger A., Lown B. Congestive heart failure caused by oral disopyramide. N Engl J Med. 1980 Mar 13;302(11):614–617. doi: 10.1056/NEJM198003133021106. [DOI] [PubMed] [Google Scholar]
  21. Rakita L., Sobol S. M., Mostow N., Vrobel T. Amiodarone pulmonary toxicity. Am Heart J. 1983 Oct;106(4 Pt 2):906–916. doi: 10.1016/0002-8703(83)90015-7. [DOI] [PubMed] [Google Scholar]
  22. Rosenbaum M. B., Chiale P. A., Halpern M. S., Nau G. J., Przybylski J., Levi R. J., Lázzari J. O., Elizari M. V. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934–944. doi: 10.1016/0002-9149(76)90807-9. [DOI] [PubMed] [Google Scholar]
  23. Rosenbaum M. B., Chiale P. A., Ryba D., Elizari M. V. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol. 1974 Aug;34(2):215–223. doi: 10.1016/0002-9149(74)90200-8. [DOI] [PubMed] [Google Scholar]
  24. Rotmensch H. H., Belhassen B., Ferguson R. K. Amiodarone--benefits and risks in perspective. Am Heart J. 1982 Nov;104(5 Pt 1):1117–1119. doi: 10.1016/0002-8703(82)90457-4. [DOI] [PubMed] [Google Scholar]
  25. Schwartz J. B., Keefe D., Harrison D. C. Adverse effects of antiarrhythmic drugs. Drugs. 1981 Jan;21(1):23–45. doi: 10.2165/00003495-198121010-00002. [DOI] [PubMed] [Google Scholar]
  26. Winkle R. A., Gradman A. H., Fitzgerald J. W. Antiarrhythmic drug effect assessed from ventricular arrhythmia reduction in the ambulatory electrocardiogram and treadmill test: comparison of propranolol, procainamide and quinidine. Am J Cardiol. 1978 Sep;42(3):473–480. doi: 10.1016/0002-9149(78)90943-8. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES